Clinical Trial Search

Primary: Number of Participants Achieving Minimally Clinically Important Difference (MCID) Improvement From Baseline Upto 6 Months — 38; 33 Participants — p=0.73

Primary: the Change From Baseline in Pain During Walking Visual Analog Scale (VAS Walking) — 3; 3 score on a scale

Primary: Change in Intraocular Pressure — 13.60; 17.94 mmHg

Primary: Change From Baseline for Air Challenge — -1.18; -1.10 units on a scale

Primary: Numeric Rating Score — 2.0; 1.2 score on a scale — p=< 0.05

Primary: Tmax Pharmacokinetic EndPoints — 1.000; 0.525 hours

Primary: Mean Estimated Glomerular Filtration Rate (eGFR) at 12 Months From Baseline — 72.13; 72.65 ml/min/1.73m^2

Primary: The Primary Outcome Measure Will be Corneal Epithelial Dye Diffusion Rate in Nanometers Per Second, for the Test and Control Eyes. — 0.0567; 0.0583 nanometers per second

Primary: Percentage of Participants With Measles Seropositivity 56 Days Post-vaccination — 98.1; 98.0 percentage of participants

Primary: Number of Delirium-free Days During the 7 Days of Evaluation — 5.5; 0 days — p=<0.001

Primary: Improvement in Lung Function - Increase in FEV1 — 0 Participants

Primary: Objective Response Rate (ORR) — 9.7; 6.9 percentage of participants — p=0.8

Primary: Pain Interference as Measured by the Brief Pain Inventory (BPI) (Intent to Treat Model) — 6.0; 6.1; 5.1; 4.8 Units on a Scale — p=0.0691

Primary: Percentage of Participants With Very Good Partial Response (VGPR) or Better Response (Complete Response (CR) + VGPR) — 50.0 percentage of participants

Primary: Participants With Device Success During Procedure Defined as the Successful Crossing of the Laser Catheter Across the Entire Length of the Stenotic Lesion — 25; 0…